Skip to main content
padlock icon - secure page this page is secure

Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell

Buy Article:

$68.00 + tax (Refund Policy)

Stem cells have an important role in cell biology, allowing tissues to be renewed by freshly created cells throughout their lifetime. The specific micro-environment of stem cells is called stem cell niche; this environment influences the development of stem cells from quiescence through stages of differentiation. Recent advance researches have improved the understanding of the cellular and molecular components of the micro-environment - or niche - that regulates stem cells. We point out an important trend to the study of niche activity in breast cancers. Breast cancer has long been known to conserve a heterogeneous population of cells. While the majority of cells that make up tumors are destined to differentiate and eventually stop dividing, only minority populations of cells, termed cancer stem cell, possess extensive self renewal capability. These cancer stem cells possess characteristics of both stem cells and cancer cells. Breast cancer stem cells reversal to breast somatic stem cells offer a new therapy, that not only can stop the spread of breast cancer cells, but also can differentiate breast cancer stem cells into normal breast somatic stem cells. These can replace damaged breast tissue. Nevertheless, the complexity of realizing this therapy approach needs further research.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ATP Binding Cassette; Breast Somatic Progenitor Cells (BSPCs); Breast somatic stem cell; Catenin; Proteomic analysis; Secreted frizzled-related; Somatic Stem Cells (SSCs); Stromal Cell-Derived Factor-1; Transforming Growth Factor; Vascular Endothelial Growth Factor; alveoli; angiogenesis; angiopoietin-1; angiopoietin-2; apoptosi; blastocyst; breast cancer stem cell; cancer stem cells; carcinogenesis; carcinoma-associated fibroblasts; chemokine receptor; chemotherapy; differentiation therapy; ductal dysplasia; ductal epithelial cells; embryogene-sis; embryonic stem cells; extra cellular matrix; homeostasis; hyperplasia; immunodeficiency disease; immunotherapy; leukemia; lobulo-alveolar structure; metalloproteinase; morphogenic capacity; multidrug resistance; non-obese diabetic; organogenesis; phenotype; pluripotent cells; sarcomas; stem cell niche; tumorigenic capacity; zebrafish-embryo protein extracts

Document Type: Research Article

Publication date: February 1, 2011

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more